Conceptio › Archive › HAL (France)
HAL (France)open access

Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study

John Harris et al.
HAL (France) · Papers · License: Open Access
Open Source ↗
0
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 126847
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.